The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. - Wikidata - wikimedia - TriplyDB

The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.

The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.

http://www.wikidata.org/entity/Q33929529

about

Radiotherapy combination opportunities leveraging immunity for the next oncology practice Targeting the indoleamine 2,3-dioxygenase pathway in cancer The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity Strategies for combining immunotherapy with radiation for anticancer therapy Biomarkers for glioma immunotherapy: the next generation The role of IDO in brain tumor immunotherapy Trial watch: IDO inhibitors in cancer therapy Targeting immune checkpoints in malignant glioma IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Effect of Necrosis on the miRNA-mRNA Regulatory Network in CRT-MG Human Astroglioma Cells.Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.Major developments in the design of inhibitors along the kynurenine pathway.Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Developing immunotherapeutic strategies to target brain tumors.Modulation of cancer-specific immune responses by amino acid degrading enzymes.Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases.IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment.The interplay between metabolic remodeling and immune regulation in glioblastoma.Aberrant Kynurenine Signaling Modulates DNA Replication Stress Factors and Promotes Genomic Instability in Gliomas.Indoleamine-2,3-dioxygenase and Interleukin-6 associated with tumor response to neoadjuvant chemotherapy in breast cancer.IDO1 in cancer: a Gemini of immune checkpoints.Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA.Discovery of IDO1 and DNA dual targeting antitumor agents.Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.The expression and prognostic relevance of indoleamine 2,3-dioxygenase in tongue squamous cell carcinoma.Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer

P2860

Q26738443-FA3249DF-4EDC-4F6D-AFDA-ABC66DB4F8FA Q26775471-96AB497A-AAE6-4F64-BDF5-99E5AF67E693 Q26785900-01F555C5-7815-4CE9-B275-53247285D0FA Q26796675-BDE6D6F9-65CC-4BC1-B269-6BE11AE4434D Q26825496-AAEB4A51-CF3A-4D40-B7FB-CC8228C5DE9A Q26830399-F7E153D9-898B-4509-946B-3C279DD38BA4 Q27006866-35DD8B21-EB62-4F9C-8D52-43D7F7E30FEF Q28072012-3E6A8F1F-28AF-4140-83AC-512444CAE4F6 Q34512092-D2EEA361-411E-410B-910E-CDF224AB3211 Q36635458-682A9ADD-5E80-4595-B9A4-63DD91CBA15E Q37079141-72427493-88FB-4489-A89F-F07C6716791F Q38433156-A3791B99-DD4C-4626-83C5-B8070DC2F72A Q38438763-D0E76F56-DAF9-4B21-B852-89030F500263 Q38808400-4DD66BA9-3A23-4536-916C-A9FB6912D24E Q38832886-55475871-A3C7-4484-8682-669CD7B066D5 Q38851464-C740081E-2C8D-4AFA-B3DE-C3FF5D0F3B6D Q39045520-1A0795C0-707F-4E06-8776-283E3565758C Q39185463-4255432E-FB78-4714-9574-AFA0767EA09A Q39294822-60FDFFC8-4081-447D-8283-EF44A17B0C90 Q39328710-BD62F576-CBE7-4E11-B45C-DED421B12852 Q41720039-44FE9F96-CBC8-4760-811A-3E736C70D7C6 Q47157830-910CC72E-A99C-4A54-87A2-D363C3C6E770 Q47836812-2D9BA8FB-A870-474E-B93F-A95D1033BD05 Q48177244-F4D86130-9958-4426-BBC6-97BF82F8BE6D Q48589619-49BBEB65-7041-4C92-B433-AB63110E59D4 Q48766890-167719E4-1B80-41CD-AE7F-8DCD54A76AE0 Q49592881-E4EAD657-7443-4CBF-A070-4D8FCD92EFD7 Q50103704-1315EE38-BC41-4159-A810-B6CBC0AC5F83 Q52579088-F53C11F1-34A6-436D-B26F-49FF474C7694 Q53146697-CE87F0A3-CBE0-4C24-AA8F-77DD26EF15EE Q55346219-62121078-5949-4F8A-A06B-0D880C5653EB Q58750429-0BEE9D15-4AD3-4135-8F84-F4CDA1E5FFD9

P2860

The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.

http://www.wikidata.org/entity/Q33929529

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The indoleamine 2,3-dioxygenas ...... y against murine glioblastoma.

@ast

The indoleamine 2,3-dioxygenas ...... y against murine glioblastoma.

@en

type

label

The indoleamine 2,3-dioxygenas ...... y against murine glioblastoma.

@ast

The indoleamine 2,3-dioxygenas ...... y against murine glioblastoma.

@en

prefLabel

The indoleamine 2,3-dioxygenas ...... y against murine glioblastoma.

@ast

The indoleamine 2,3-dioxygenas ...... y against murine glioblastoma.

@en

P1433

Q33929529-C58B15F1-A917-46CF-9E53-EE8FDD3B1DDC

P1476

Q33929529-D2B57764-63AC-4487-AAFE-2E00D5883751

P2093

Q33929529-268B6A05-E2DB-4D68-BBC6-84AD07F5D512

Q33929529-525161FF-6C68-4F4A-8436-4889D9C06110

Q33929529-5B565D68-A54F-4860-A35F-795AE3317943

Q33929529-606C6C25-BBC2-4DE7-A480-D6AA5E59D3C2

Q33929529-7AB41F84-8D7D-493E-B3A1-588A464FB294

Q33929529-847C5AFA-A3DB-463B-8677-80BABDEFC4C7

Q33929529-8C83CA6F-2D89-4D18-9423-65C90F361708

Q33929529-8E806914-C133-4282-B280-78EF60478289

Q33929529-8F1E6990-E2DF-418D-9AC4-D08DF7F914E7

Q33929529-939C0D70-5A59-4AD3-89D4-9D32862A2AB4

P2860

Q33929529-00012307-5B62-4FDD-8380-EEBD8F0FE542

Q33929529-085DC368-87C4-4E62-B941-9488E5801548

Q33929529-11AB9A93-B56E-4718-9363-1AC37ED2A264

Q33929529-26FA50AE-917F-4865-8FAE-C25EA61F17EB

Q33929529-3937F9D3-4409-465E-91B1-09F9C89D5BEA

Q33929529-444B4340-9A70-4DF4-86D0-02EA5D03B446

Q33929529-551762C4-08E5-4AC2-B799-4E7B1EF46445

Q33929529-574436BB-0350-4AFB-9B2B-3986AE40A6DE

Q33929529-592D0465-3695-4BA3-8511-EB0564B14189

Q33929529-699D1721-6762-4CF3-AD80-2650EC40053E

P2888

Q33929529-3B84DB1C-ED24-4DEE-8C42-5526D7D35D8B

P304

Q33929529-7556CE59-A90F-43F5-8560-C2638DD416E7

P31

Q33929529-4F3EDCAA-5DF7-47B0-858E-9F500DBE6139

P356

Q33929529-D4A66375-870C-4CF3-AFF3-0F39DF952F87

P478

Q33929529-14C3EB23-4D3D-4E1F-B780-D50A49CF46CF

P50

Q33929529-EFFCD475-F07B-4112-865C-E1D61E7DBACA

P577

Q33929529-2008A536-B9AF-4933-A2AB-2440ADD24B5F

P5875

Q33929529-01E6D715-D3DB-48E6-914F-E710A62ABB4A

P6179

Q33929529-E88E696B-8864-4253-8970-683F69A73DE6

P698

Q33929529-E73A7186-71AE-4B07-9170-3E9A16650DA0

P921

Q33929529-44C9BEE2-FA17-40BD-9F23-076EB6DF10BF

P932

Q33929529-F8CFF4E6-FB65-4C62-86C6-36DF80652223

P356

P1433

Journal for Immunotherapy of Cancer

P1476

The indoleamine 2,3-dioxygenas ...... y against murine glioblastoma.

@en

P2093

Aaron R Bolduc

http://www.w3.org/2001/XMLSchema#string

Amyn M Rojiani

http://www.w3.org/2001/XMLSchema#string

Andrew L Mellor

http://www.w3.org/2001/XMLSchema#string

Anna K Bolduc

http://www.w3.org/2001/XMLSchema#string

Bernard L Maria

http://www.w3.org/2001/XMLSchema#string

Claire Ashley

http://www.w3.org/2001/XMLSchema#string

David H Munn

http://www.w3.org/2001/XMLSchema#string

David McCall

http://www.w3.org/2001/XMLSchema#string

Denise N Gamble

http://www.w3.org/2001/XMLSchema#string

Kelly Hoang

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of allogeneic fetal rejection by tryptophan catabolism

Kynurenine is an endothelium-derived relaxing factor produced during inflammation

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses

Expression of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase in early concepti

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells.

P2888

P304

21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2051-1426-2-21

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263697592

http://www.w3.org/2001/XMLSchema#string

P6179

1013032450

http://www.w3.org/2001/XMLSchema#string

P698

25054064

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

4105871

http://www.w3.org/2001/XMLSchema#string